Selective inhibition of NF‐κB suppresses bone invasion by oral squamous cell carcinoma in vivo
Open Access
- 19 January 2012
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 131 (5) , E625-E635
Abstract
Nuclear factor‐κB (NF‐κB) is constitutively activated in many cancers, including oral squamous cell carcinoma (OSCC), and is involved in the invasive characteristics of OSCC, such as growth, antiapoptotic activity and protease production. However, the cellular mechanism underlying NF‐κB's promotion of bone invasion by OSCC is unclear. Therefore, we investigated the role of NF‐κB in bone invasion by OSCC in vivo. Immunohistochemical staining of OSCC invading bone in 10 patients indicated that the expression and nuclear translocation of p65, a main subunit of NF‐κB, was increased in OSCC compared with normal squamous epithelial cells. An active form of p65 phosphorylated at serine 536 was present mainly in the nucleus in not only differentiated tumor cells but also tumor‐associated stromal cells and bone‐resorbing osteoclasts. We next injected mouse OSCC SCCVII cells into the masseter region of C3H/HeN mice. Mice were treated for 3 weeks with a selective NF‐κB inhibitor, NBD peptide, which disrupts the association of NF‐κB essential modulator (NEMO) with IκB kinases. NBD peptide treatment inhibited TNFα‐induced and constitutive NF‐κB activation in SCCVII cells in vitro and in vivo, respectively. Treatment with NBD peptide decreased zygoma and mandible destruction by SCCVII cells, reduced number of osteoclasts by inhibiting RANKL expression in osteoblastic cells and SCCVII cells, increased apoptosis and suppressed the proliferation of SCCVII cells. Taken together, our data clearly indicate that inhibition of NF‐κB is useful for inhibiting bone invasion by OSCC.Keywords
This publication has 36 references indexed in Scilit:
- NF-κB, Inflammation, and Metabolic DiseaseCell Metabolism, 2011
- Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck CancerJournal of Clinical Oncology, 2010
- Inhibitor of κB Kinase Beta Regulates Gastric Carcinogenesis via Interleukin-1α ExpressionGastroenterology, 2010
- Roles of Interleukin-6 and Parathyroid Hormone-Related Peptide in Osteoclast Formation Associated with Oral CancersThe American Journal of Pathology, 2010
- The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinomaBMC Cancer, 2009
- Recent Advances in Head and Neck CancerNew England Journal of Medicine, 2008
- NF-κB and cancer — identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Nuclear factor-κB and liver carcinogenesisCancer Letters, 2005
- RANKL and RANK as novel therapeutic targets for arthritisCurrent Opinion in Rheumatology, 2003
- Osteoclast differentiation and activationNature, 2003